Ariad Pharmaceuticals, Inc. And Medinol Ltd. Announce Initiation Of Two Registration Trials Of The Nirsupreme&#0153 Ridaforolimus-Eluting Stent For Use In Coronary Artery Disease

Published: Jan 14, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass. & TEL AVIV, Israel--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medinol, Ltd. today announced the initiation of two registration trials of Medinol’s NIRsupremeTM Ridaforolimus-Eluting Coronary Stent System incorporating ARIAD’s mTOR inhibitor, ridaforolimus. The two NIRsupreme clinical trials are randomized, single-blind, global studies taking place in the United States, Europe, Israel and Canada and will enroll approximately 2,200 patients with coronary artery disease. ARIAD licensed ridaforolimus to Medinol for use in drug-eluting stents in 2005. Drug-eluting stents (DES) are now implanted in over 500,000 patients yearly in the United States.

Help employers find you! Check out all the jobs and post your resume.

Back to news